{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:09:26Z","timestamp":1792433366063,"version":"4.5.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Idiopathic multicentric Castleman disease (iMCD) is a rare heterogeneous disorder involving multicentric lymphadenopathy, systemic inflammation, and cytokine-driven organ dysfunction. Despite the approval of siltuximab, a monoclonal antibody against interleukin-6, for the treatment of iMCD, it is not known how long patients should receive siltuximab before determining whether the treatment is beneficial and should be continued. We performed post hoc analyses of the phase 2 randomized double-blind placebo-controlled trial of siltuximab for the treatment of patients with iMCD to determine the sequence of normalization of laboratory, clinical, and lymph node responses in patients who responded to siltuximab. Seventy-nine patients were enrolled in the trial (siltuximab, n = 53; placebo plus best supportive care, n = 26). Progression-free survival (PFS) was significantly improved in siltuximab-treated patients compared with those receiving placebo (P = .0001). The median PFS was 14.5 months (95% confidence interval, 13.6 months to upper bound not reached) for patients receiving placebo but was not reached for patients receiving siltuximab. In siltuximab-treated patients who achieved durable tumor (radiologic) and symptomatic responses (18 [34%] of 53), the median time to normalization of abnormal laboratory tests and clinical end points occurred in the following sequence: thrombocytosis, symptomatic response, elevated C-reactive protein, hypoalbuminemia, anemia, lymph node response, hyperfibrinogenemia, and elevated immunoglobulin G. Siltuximab treatment prolongs PFS, rapidly improves symptomatology, and provides meaningful clinical benefit despite some laboratory tests and enlarged lymph nodes taking months to normalize in treatment responders. These data support the continued frontline use of siltuximab for iMCD, as recommended by international guidelines. This trial was registered at www.clinicaltrials.gov as #NCT01024036.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007112","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T18:01:16Z","timestamp":1657130476000},"page":"4773-4781","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease"],"prefix":"10.1182","volume":"6","author":[{"given":"Frits","family":"van Rhee","sequence":"first","affiliation":[{"name":"1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"2Cancer Research and Biostatistics, West Lake Union Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5300-975X","authenticated-orcid":false,"given":"Karan","family":"Kanhai","sequence":"additional","affiliation":[{"name":"3Medical Affairs, EUSA Pharma, Hemel Hempstead, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6397-6885","authenticated-orcid":false,"given":"Rabecka","family":"Martin","sequence":"additional","affiliation":[{"name":"3Medical Affairs, EUSA Pharma, Hemel Hempstead, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Nishimura","sequence":"additional","affiliation":[{"name":"2Cancer Research and Biostatistics, West Lake Union Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Hoering","sequence":"additional","affiliation":[{"name":"2Cancer Research and Biostatistics, West Lake Union Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[{"name":"4Center for Cytokine Storm Treatment & Laboratory, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"issue":"12","key":"2022081715220615800_B1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood."},{"issue":"1","key":"2022081715220615800_B2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hoc.2017.09.003","article-title":"The role of interleukin-6 in Castleman disease","volume":"32","author":"Yoshizaki","year":"2018","journal-title":"Hematol Oncol Clin North Am."},{"issue":"4","key":"2022081715220615800_B3","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman\u2019s disease: a systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol."},{"issue":"2","key":"2022081715220615800_B4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/bloodadvances.2021004441","article-title":"Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy","volume":"6","author":"Mukherjee","year":"2022","journal-title":"Blood Adv."},{"issue":"11","key":"2022081715220615800_B5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman\u2019s disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol."},{"issue":"13","key":"2022081715220615800_B6","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2022081715220615800_B7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol."},{"issue":"3","key":"2022081715220615800_B8","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S2352-3026(19)30257-1","article-title":"Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials","volume":"7","author":"van Rhee","year":"2020","journal-title":"Lancet Haematol."},{"issue":"5","key":"2022081715220615800_B9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022081715220615800_B10","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2016-11-748855","article-title":"Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease","volume":"129","author":"Yu","year":"2017","journal-title":"Blood."},{"key":"2022081715220615800_B11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/PROM.S140011","article-title":"Impact of siltuximab on patient-related outcomes in multicentric Castleman\u2019s disease","volume":"9","author":"Sitenga","year":"2018","journal-title":"Patient Relat Outcome Meas."},{"issue":"3","key":"2022081715220615800_B12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/10428194.2021.1999437","article-title":"A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed\/refractory iMCD","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk Lymphoma."},{"issue":"23","key":"2022081715220615800_B13","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman\u2019s disease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol."},{"key":"2022081715220615800_B14","author":"Fajgenbaum","journal-title":"Br J Haematol."},{"issue":"12","key":"2022081715220615800_B15","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1080\/10428194.2021.1941926","article-title":"Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation","volume":"62","author":"Ostrowska","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"20","key":"2022081715220615800_B16","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2023010152","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/16\/4773\/1913922\/advancesadv2022007112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/16\/4773\/1913922\/advancesadv2022007112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T15:22:27Z","timestamp":1660749747000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/16\/4773\/485794\/Siltuximab-is-associated-with-improved-progression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":16,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,8,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007112","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2023010152","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]}}}